The US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Tecvayli (teclistamab-cqyv) for a reduced dosin 21 February 2024
Australia’s Starpharma has announced that it has completed the formal dispute resolution process with the US Food and Drug Administration (FDA) in relation to V 20 February 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.